Stay updated on MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3, indicating a newer version of the page.SummaryDifference0.1%

- Check20 days agoChange DetectedThe page revision changed from v3.6.0 to v3.6.2, signaling a backend version update. No user-facing content or behavior was modified.SummaryDifference0.1%

- Check34 days agoChange DetectedRecruitment status updated to not currently enrolling participants. New navigation sections—How to Read a Study Record, Common Questions, and How to Join a Study—were added, and the Intervention/Treatment heading formatting was updated along with the revision label from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check41 days agoChange DetectedThe page’s revision number was updated from v3.5.4 to v3.5.5, signaling a backend release with no impact on the study data or user-facing information.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page revision label changes from v3.5.3 to v3.5.4, indicating a new version of the page rather than substantive changes to the study details.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page’s revision/version label has been updated from v3.5.2 to v3.5.3, reflecting a deployed update to the page. No changes to the study details or other substantive content are indicated.SummaryDifference0.1%

Stay in the know with updates to MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.